Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel

Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001)

Excellent safety profile. No treatment related adverse events

Brighton, United Kingdom – 29th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces positive top-line results from its Phase 2b clinical study testing its XF-73 nasal gel as a new product for the prevention of the incidence of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA). The primary efficacy endpoint was met with an exceptionally high statistical significance and there were no treatment related safety events.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...